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Abstract 
Sepsis  related  coagulopathy  ranges  from
mild  laboratory  alterations  up  to  severe  dis-
seminated  intravascular  coagulation  (DIC).
There is evidence that DIC is involved in the
pathogenesis  of  microvascular  dysfunction
contributing to organ failure. Additionally, the
systemic activation of coagulation, by consum-
ing  platelets  and  coagulation  factors,  may
cause bleeding. Thrombin generation via the
tissue  factor/factor  VIIa  route,  contemporary
depression of antithrombin and protein C anti-
coagulant systems, as well as impaired fibrin
degradation, due to high circulating levels of
PAI-1,  contribute  to  enhanced  intravascular
fibrin deposition. This deranged coagulopathy
is an independent predictor of clinical outcome
in patients with severe sepsis. Innovative sup-
portive strategies aiming at the inhibition of
coagulation activation should comprise inhibi-
tion  of  tissue  factor-mediated  activation  or
restoration  of  physiological  anticoagulant
pathways, as the administration of recombi-
nant  human  activated  protein  C  or  concen-
trate. In spite of some promising initial stud-
ies, additional trials are needed to define their
clinical  effectiveness  in  adults  and  children
with severe sepsis.  
Introduction
Sepsis  always  leads  to  deranged  coagula-
tion,  ranging  from  mild  alterations  up  to
severe disseminated intravascular coagulation
(DIC).  Septic  patients  with  severe  DIC  can
present with manifest thromboembolic disease
as purpura fulminans or clinically less appar-
ent microvascular fibrin deposition, predomi-
nantly presenting as multiple organ dysfunc-
tion.  Alternatively,  severe  bleeding  might  be
the leading symptom, or even coexisting bleed-
ing and thrombosis.1,2 The  deranged coagula-
tion,  particularly  DIC,  is  an  important  and
independent predictor of clinical outcome in
patients with severe sepsis.3-5
Mechanism of coagulation activa-
tion in DIC
Initiation  of  coagulation  triggered  by  pro-
inflammatory cytokines such as IL-6, is tissue
factor (TF) dependent. Amplification of throm-
bin generation is due to tumor necrosis factor
(TNF-a) impaired defective physiological anti-
coagulant  mechanisms  while  propagation  of
fibrin  deposition  in  the  microvasculature  is
caused by insufficient fibrin degradation, as a
result of an inhibited fibrinolytic system.6-9
The  TF-factor-VIIa  complex  catalyses  the
activation of both factors IX and X, enhancing
activation  of  factors  X  and  prothrombin,
respectively. Inducible TF is mainly expressed
by  monocytes  and  macrophages,  and  its
expression on monocytes is stimulated by the
presence of platelets and granulocytes in a P-
selectin-dependent  reaction.  This  cellular
interaction  also  enhances  the  production  of
interleukins  IL-1b  and  IL-8,  and  of  tumor
necrosis factor a (TNFa). 
Dysfunctional anticoagulant pathways
Systemic  activation  of  coagulation  upon
inflammation  is  counteracted  by  several
inhibitors such as antithrombin (AT), proteins
C and S, and tissue factor pathway inhibitor
(TFPI).
Markedly lowered plasma levels of AT are
found in sepsis as a result of both reduced pro-
tein synthesis and increased clearance. Under
the influence of cytokines, the synthesis of gly-
cosaminoglycans  by  endothelial  cells  is
reduced, impairing the inhibitory potential of
AT. Protein C and its cofactor protein S repre-
sents a further defence mechanism. Thrombin
binds to the endothelial cell-membrane-associ-
ated molecule thrombomodulin, and this com-
plex converts protein C to its active form, acti-
vated protein C (APC). APC inactivates factors
Va and VIIIa by proteolytic cleavage, thus slow-
ing the coagulation cascade. Endothelial cells,
primarily  of  large  blood  vessels,  express  an
endothelial protein C receptor (EPCR) which
augments the activation of protein C at the cell
surface. In patient studies, lowered levels of
protein C and protein S are associated with
increased mortality. 
A third inhibitory mechanism, TFPI, inhibits
the TF-factor VIIa complex by forming a quater-
nary complex with factor Xa. A study in human
subjects  confirmed  the  potential  of  TFPI  to
block the procoagulant pathway triggered by
endotoxin, by binding endotoxin and attenuat-
ing Il-6 generation.9,10
Dysfunctional fibrinolysis
There is evidence that fibrinolysis is activat-
ed in experimental models of severe infection.
This is demonstrated by an initial activation of
plasminogen activation followed by a marked
impairment,  caused  by  the  release  of  plas-
minogen  activator  inhibitor,  type  1  (PAI-1),
causing  a  net  procoagulant  situation.  The
molecular  basis  is  cytokine-mediated  activa-
tion  of  vascular  endothelial  cells.  Endotoxin
and  TNFa  stimulate  PAI-1  production  in  the
liver, kidney, lung and adrenals of mice. PAI-1
is the principal inhibitor of fibrinolysis. Recent
studies have shown that a functional mutation
in the PAI-1 gene (the 4G/5G polymorphism)
not only influenced the plasma levels of PAI-1
but  was  also  linked  to  clinical  outcome  of
meningococcal septicemia.11
Platelet activation 
Endotoxin  can  directly  activate  platelets,
and  many  pro-inflammatory  cytokines  are
capable  of  inducing  platelet  activation.  The
provision of a suitable phospholipid surface on
the activated platelet membrane permits the
assembly  of  complexes  of  activated  coagula-
tion factors, catalyses the generation of throm-
bin several-fold and renders the coagulation
system less susceptible to inhibitors.12
Inflammation and coagulation
interaction in DIC
Coagulation  proteases  and  protease
inhibitors interact also with specific cell recep-
tors to induce signaling pathways.12 Factor Xa,
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thrombin and the TF-factor VIIa complex elicit
pro-inflammatory activities. Activated protein
C has anti-inflammatory effects on mononu-
clear cells and granulocytes, distinct from its
anticoagulant activity. This anti-inflammatory
activity occurs only when APC gets in contact
with its receptor EPCR and activates protease-
activated  receptor  PAR-1,  which  inhibits
inflammation and apoptosis.13 Several coagu-
lation proteases can induce pro-inflammatory
mediators with procoagulant effects which fur-
ther maintain and amplify DIC. 
Implications for therapy
In  case  of  severe  systemic  inflammatory
response syndrome, the coagulation abnormali-
ties and consequent organ dysfunction might
proceed even after initiation of causative agent
treatment. Supportive measures to manage the
coagulopthy are required which might positive-
ly affect morbidity and mortality (Table 1).
Plasma, coagulation factors and platelet
substitution therapy
Low levels of platelets and coagulation fac-
tors  might  increase  the  risk  of  bleeding.
However, plasma or platelet substitution thera-
py  is  indicated  only  in  patients  with  active
bleeding or at high risk for bleeding complica-
tions. It might be necessary to use large vol-
umes  of  plasma  to  correct  the  coagulation
defect. Coagulation factor concentrates, such
as prothrombin complex concentrate may be
used, but these compounds lack essential fac-
tors, such as factor V. Specific deficiencies in
coagulation factors, such as fibrinogen, can be
corrected by administration of purified coagu-
lation factor concentrates or cryoprecipitate.5
Repeated  measurement  of  prothrombin
time and activated partial thromboplastin time
can be useful in monitoring the coagulation
defect. In case of a (relative) vitamin K defi-
ciency,  administration  of  vitamin  K  is
required.5
Platelet  transfusion  can  be  considered  in
patients with DIC and severe thrombocytope-
nia, in particular in patients with bleeding or
in patients at risk for bleeding. The threshold
for transfusing platelets depends on the clini-
cal condition of the patient. In general, platelet
transfusions are administered to patients who
bleed and who have a platelet count of <50ﾥ
109/L. In non-bleeding patients, a much lower
threshold for platelet transfusion is used (usu-
ally 10-20ﾥ109/L), which is based on random-
ized controlled trials in patients with thrombo-
cytopenia following chemotherapy.5
Use of anticoagulants
A beneficial effect of heparin on clinically
important outcome events in patients with DIC
has  never  been  demonstrated  in  controlled
clinical trials. Also, the safety of heparin treat-
ment is controversial in DIC patients who are
prone  to  bleeding.  Therapeutic  doses  of
heparin may be indicated in patients with clin-
ically overt thromboembolism or extensive fib-
rin deposition, like purpura fulminans or acral
ischemia.  Patients  with  DIC  might  benefit
from  prophylaxis  to  prevent  venous  throm-
boembolism. 
Theoretically, the most logical anticoagulant
agent  to  use  in  DIC  is  directed  against  TF
activity. Potential agents include recombinant
TFPI, inactivated factor VIIa, and recombinant
NAPc2, a potent and specific inhibitor of the
ternary  complex  between  TF-factor  VIIa  and
factor Xa. In spite of initial promising results,
a completed trial did not show an overall sur-
vival  benefit  in  patients  with  sepsis  treated
with recombinant TFPI. Interestingly, in an a
priori  defined  subgroup  of  patients  with  an
international  normalized  ratio  of  more  than
1.2, TFPI treatment was associated with a more
favorable outcome.14,15
Restoration of anticoagulant pathways
The use of AT concentrates in patients with
DIC  and  sepsis  has  been  extensively  stud-
ied.16,17 All trials show some beneficial effect
in  improvement  of  laboratory  parameters,
shortening  of  the  duration  of  DIC,  or  even
improvement in organ function. A large-scale,
multicenter, randomized controlled trial (RCT)
showed no significant reduction in mortality of
septic  patients  treated  with  AT  concentrate.
Surprisingly,  subgroup  analyses  indicated
some benefit in patients who did not receive
concomitant  heparin,  but  this  observation
needs prospective validation.
A beneficial effect of recombinant human
activated protein C was demonstrated in sever-
al  randomized  controlled  trials.18-23
Interestingly, a markedly greater reduction in
D-dimer levels and IL-6 was seen at all time
points studied in patients receiving activated
protein C, indicating its beneficial effect on
activation of coagulation and its anti-inflam-
matory effect in patients with sepsis. However
a recently updated review24 including a total of
five RCTs involving 5,101 participants showed
that for 28-day mortality, APC did not reduce
the risk of death in adult and pediatric patients
with  severe  sepsis.  APC  use  was  associated
with an increased risk of bleeding (P=0.01).
Moreover, the recent randomized multination-
al trial, the Prowess-shock trial,25 found no sig-
nificant  reduction  in  mortality  in  treated
patients  compared  to  placebo  and  the  drug
Company has withdrawn drotrecogin alfa from
the market by november 2011. To avoid bleed-
ing risk and in alternative to the activated form
there is a rationale to use protein C zymogen
in severe sepsis. In a double blind randomized
study, 40 children with purpura fulminans and
septic shock were randomized to receive place-
bo or non-activated protein C concentrate at
various  dosages,  and  in  all  treated  patients
conversion to activated form was observed, sig-
nificantly  correlated  with  drug  dosage.26 A
novel randomized prospective study on the out-
come and changes in clotting and inflammato-
ry parameters in children with severe sepsis
receiving protein C concentrate is ongoing in
Italy  (Pediatric  Intensive  Care  C  protein
HEmostasis PICCHE Study) and immune sup-
pressed patients are also included.
Inhibitors of inflammation 
TM by binding to thrombin converts protein
C to APC and inhibits inflammatory process. In
a  randomized  controlled  study  recombinant
TM (rTM) significantly improved DIC, particu-
larly in controlling bleeding. Further inhibitors
of inflammation being investigated are antise-
lectin antibodies, which when associated with
heparin may block leukocyte and platelet adhe-
sion, and interleukin-10, which prevents coag-
ulation activation induced by endotoxemia. 
Review
Table 1. Supportive treatment recommendations for sepsis induced coagulopathy.
Plasma In patients with active bleeding Not for prophylaxis
Coagulation factor  In patients with active bleeding Not recommended for
concentrates  and with specific deficiencies prophylaxis
or cryoprecipitate in coagulation factors
Platelets In patients with thrombocytopenia and  In non-bleeding patients when platelets
active bleeding or at high risk   <10-20ﾥ109/L.
for bleeding complications
Vitamin K  In case of relative deficiency
Heparin In patients with purpura fulminans or  Prophylaxis of venous
acral ischemia in absence of bleeding  thromboembolism
or of high  bleeding risk
Antithrombin In case of severe deficiency Not recommended for prophylaxis
Recombinant  Drug withdrawn by manufacturer
activated Protein C 
Protein C  In children with severe  PICCHE (Pediatric Intensive Care
concentrate shock and high risk mortality C protein HEmostasis) 
(dysfunction at least 2 organs)  Study ongoing in Italy[Pediatric Reports 2011; 3:e30] [page 121]
Conclusions
Management of sepsis related coagulopathy
should  take  into  consideration  combination
treatments aimed at inhibition of TF activated
coagulation in combination with restoration of
anticoagulant  pathways,  as  well  as  cytokine
removal. In spite of promising results from ini-
tial  studies,  additional  trials  are  needed  to
define their clinical effectiveness in children
with severe sepsis. 
References
1. Levi M. Current understanding of dissem-
inated  intravascular  coagulation.  Br  J
Haematol 2004;124:567-76.
2. Zeverleder  S,  Hack  CE,  Willemin  WA.
Disseminated intravascular coagulation in
sepsis. Chest 2005;128:2864-75.
3. Fourrier F, Chopin C, Goudemand J, et al.
Septic shock, multiple organ failure, and
disseminated  intravascular  coagulation.
Compared  patterns  of  antithrombin  III,
protein  C,  and  protein  S  deficiencies.
Chest 1992;101:816-23.
4. Mann KG. Biochemistry and physiology of
blood  coagulation.  Thromb  Haemost
1999;82:165-74.
5. Levi M, de Jonge E, van der Poll T. Plasma
and plasma components in the manage-
ment of disseminated intravascular coagu-
lation. Best Practice  Res Clin Haematol
2006;19:127-42
6. Franco RF, de JE, Dekkers PE, et al. The in
vivo  kinetics  of  tissue  factor  messenger
RNA  expression  during  human  endotox-
emia: relationship with activation of coag-
ulation. Blood 2000;96:554-9.
7. Neumann  FJ,  Marx  N,  Gawaz  M,  et  al.
Induction of cytokine expression in leuko-
cytes  by  binding  of  thrombin-stimulated
platelets. Circulation 1997;95:2387-94.
8. Aird  WC.  Vascular  bed-specific  hemosta-
sis: role of endothelium in sepsis patho-
genesis. Crit Care Med 2001;29:S28-S34.
9. Broze  GJ  Jr.  Tissue  factor  pathway
inhibitor and the revised theory of coagu-
lation. Ann Rev Med 1995;46:103-12.
10. de Jonge E, Dekkers PE, Creasey AA, et al.
Tissue  factor  pathway  inhibitor  (TFPI)
dose-dependently  inhibits  coagulation
activation  without  influencing  the  fibri-
nolytic  and  cytokine  response  during
human endotoxemia. Blood 2000;95:1124-
9.
11. Hermans PW, Hibberd ML, Booy R, et al.
4G/5G promoter polymorphism in the plas-
minogen-activator  inhibitor-1  gene  and
outcome  of  meningococcal  disease.
Meningococcal  Research  Group.  Lancet
1999;354:556-60.
12. Coughlin  SR.  Thrombin  signalling  and
protease-activated  receptors.  Nature
2000;407:258-64.
13. Rezaie  AR.  Regulation  of  the  protein  C
anticoagulant and antinflammatory path-
ways. Curr Med  Chem 2010;17:2059-69.
14. Abraham E, Reinhart K, Svoboda P, et al.
Assessment of the safety of recombinant
tissue factor pathway inhibitor in patients
with severe sepsis: a multicenter, random-
ized, placebo-controlled, single-blind, dose
escalation  study.  Crit  Care  Med
2001;29:2081-9.
15. Abraham  E,  Reinhart  K,  Opal  S,  et  al.
Efficacy and safety of tifacogin (recombi-
nant  tissue  factor  pathway  inhibitor)  in
severe  sepsis:  a  randomized  controlled
trial. JAMA 2003;290:238-47.
16. Warren BL, Eid A, Singer P, et al. Caring for
the  critically  ill  patient  High-dose
antithrombin III in severe sepsis: a ran-
domized  controlled  trial.  JAMA
2001;286:1869-78.
17. Wiedermann CJ, Kaneider NC. A systemat-
ic review of antithrombin concentrate use
in patients with disseminated intravascu-
lar  coagulation  of  severe  sepsis.  Blood
Coagul Fibrinol  2006;17:521-6. 
18. Gross  SJ,  Filston  HC,  Anderson  JC.
Controlled study of treatment for dissemi-
nated  intravascular  coagulation  in  the
neonate. J Pediatr 1982;100:445-8.
19. Bernard GR, Vincent JL, Laterre PF, et al.
for the recombinant human activated pro-
tein C worldwide evaluation in severe sep-
sis (PROWESS) study group. Efficacy and
safety  of  recombinant  human  activated
protein C for severe sepsis. N Engl J Med
2001;344:699-709.
20. Bernard  GR,  Ely  EW,  Wright  TJ,  et  al.
Safety and dose relationship of recombi-
nant human activated protein C for coagu-
lopathy  in  severe  sepsis.  Crit  Care  Med
2001;29:2051-9.
21. Dhainaut  JF,  Yan  SB,  Joyce  DE,  et  al.
Treatment effects of drotrecogin alfa (acti-
vated) in patients with severe sepsis with
or without overt disseminated intravascu-
lar  coagulation.  J  Thromb  Haemost
2004;21924-33. 
22. Vincent  JL,  Angus  DC,  Artigas  A,  et  al.
Effects of drotrecogin alfa (activated) on
organ dysfunction in the PROWESS trial.
Crit Care Med 2003;31:834-40.
23. Levi  M.  Benefit  of  recombinant  human
activated protein C beyond 28-day mortali-
ty: there is more to life than death. Crit
Care Med 2003;31:984-5. 
24. Martí-Carvajal  AJ,  Solà  I,  Lathyris  D,
Cardona AF. Human recombinant activated
protein  C  for  severe  sepsis.  Cochrane
Database  of  Systematic  Reviews  2011,
issue 4, art. CD004388. 
25. Silva  E,  de  Figueiredo  LF,  Colombari  F.
Prowess-shock  trial:  a  protocol  overview
and perspectives. Shock 2010;34:48-53.
26. de Kleijn ED, de Groot R, Hack CE, et al.
Activation of protein C following infusion
of protein C concentrate in children with
severe meningococcal sepsis and purpura
fulminans: a randomized, double-blinded,
placebo-controlled, dose-finding study. Crit
Care Med  2003;31:1839-47. 
Review